See more : Lombard & Medot SA (MLCAC.PA) Income Statement Analysis – Financial Results
Complete financial analysis of BioCardia, Inc. (BCDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioCardia, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- CV Holdings, Inc. (CVHL) Income Statement Analysis – Financial Results
- Ocean Bio-Chem, Inc. (OBCI) Income Statement Analysis – Financial Results
- FG Group Holdings Inc. (FGH) Income Statement Analysis – Financial Results
- WildBrain Ltd. (WILD.TO) Income Statement Analysis – Financial Results
- UK Mortgages Ltd (UKML.L) Income Statement Analysis – Financial Results
BioCardia, Inc. (BCDA)
About BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 477.00K | 1.35M | 1.02M | 145.00K | 710.00K | 625.00K | 479.00K | 576.00K | 517.00K | 427.00K | 268.00K | 62.00K | 12.00K | 0.00 | 1.87M | 1.27M | 643.00K | 0.00 | 0.00 | 0.00 | 3.76M | 4.08M | 3.96M | 3.87M | 3.99M | 4.20M | 3.80M | 3.40M | 3.15M |
| Cost of Revenue | 7.73M | 11.90M | 640.00K | 4.00K | 358.00K | 517.00K | 690.00K | 746.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 380.00K | 197.00K | 130.00K | 0.00 | 0.00 | 0.00 | 860.33K | 1.01M | 971.26K | 952.26K | 898.17K | 1.00M | 900.00K | 800.00K | 727.61K |
| Gross Profit | -7.25M | -10.55M | 375.00K | 141.00K | 352.00K | 108.00K | -211.00K | -170.00K | 517.00K | 427.00K | 268.00K | 62.00K | 12.00K | 0.00 | 1.49M | 1.07M | 513.00K | 0.00 | 0.00 | 0.00 | 2.90M | 3.07M | 2.99M | 2.91M | 3.09M | 3.20M | 2.90M | 2.60M | 2.42M |
| Gross Profit Ratio | -1,519.71% | -780.25% | 36.95% | 97.24% | 49.58% | 17.28% | -44.05% | -29.51% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 79.67% | 84.46% | 79.78% | 0.00% | 0.00% | 0.00% | 77.12% | 75.32% | 75.46% | 75.37% | 77.48% | 76.19% | 76.32% | 76.47% | 76.89% |
| Research & Development | 7.73M | 8.83M | 8.56M | 9.81M | 8.56M | 8.45M | 5.80M | 3.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00M | 1.33M | 215.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.73M | 0.00 | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.40M | 4.42M | 5.09M | 5.86M | 6.00M | 5.76M | 6.40M | 4.11M | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 5.59M | 3.91M | 610.00K | 79.80K | 98.18K | 101.48K | 3.59M | 3.58M | 4.14M | 4.93M | 4.90M | 4.30M | 4.00M | 3.20M | 2.21M |
| Other Expenses | 0.00 | -6.00K | -2.00K | -2.00K | -2.00K | -3.00K | 2.00K | -2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.37K | 0.00 | 85.72K | 0.00 | 0.00 | 0.00 | 115.45K | 100.00K | 100.00K | 100.00K | 0.00 |
| Operating Expenses | 12.12M | 13.25M | 13.65M | 15.67M | 14.57M | 14.21M | 12.19M | 7.44M | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 6.59M | 5.25M | 825.00K | 79.80K | 92.80K | 101.48K | 3.68M | 3.58M | 4.14M | 4.93M | 5.02M | 4.40M | 4.10M | 3.30M | 2.21M |
| Cost & Expenses | 12.12M | 13.25M | 13.65M | 15.67M | 14.92M | 14.73M | 12.88M | 8.18M | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 6.97M | 5.44M | 955.00K | 79.80K | 92.80K | 101.48K | 4.54M | 4.58M | 5.11M | 5.88M | 5.91M | 5.40M | 5.00M | 4.10M | 2.94M |
| Interest Income | 0.00 | 0.00 | 9.00K | 21.00K | 87.00K | 118.00K | 95.00K | 0.00 | 3.00K | 3.00K | 10.00K | 8.00K | 11.00K | 0.00 | 0.00 | 0.00 | 33.00K | 4.36K | 5.37K | 1.70K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 6.00K | 0.00 | 3.00K | 112.00K | 0.00 | 95.00K | 1.74M | 3.00K | 3.00K | 10.00K | 8.00K | 25.00K | 27.00K | 24.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 32.00K |
| Depreciation & Amortization | 84.00K | 377.00K | 640.00K | 566.00K | 551.00K | 203.00K | 78.00K | 39.00K | 0.00 | 0.00 | 0.00 | 0.00 | 11.00K | 967.00K | 1.21M | 561.00K | 61.00K | 0.00 | 0.00 | 0.00 | 71.08K | 84.93K | 101.83K | 107.91K | 115.45K | 100.00K | 100.00K | 100.00K | 49.74K |
| EBITDA | -11.56M | -11.82M | -12.57M | -14.44M | -14.05M | -13.90M | -12.23M | -8.54M | 319.00K | 231.00K | 9.00K | -339.00K | -618.00K | 384.00K | -3.90M | -3.61M | -218.00K | -79.80K | -92.80K | -101.48K | -99.79K | -443.03K | -418.80K | -1.05M | -1.91M | -1.81M | -1.10M | -1.00M | -600.00K |
| EBITDA Ratio | -2,423.48% | -880.25% | -1,237.73% | -10,649.66% | -1,974.23% | -2,223.84% | -2,573.49% | -1,146.70% | 61.70% | 54.10% | 3.36% | -546.77% | -5,058.33% | 0.00% | -208.40% | -170.11% | -33.90% | 0.00% | 0.00% | 0.00% | -18.08% | -10.86% | -24.66% | -50.88% | -54.95% | -23.81% | -42.11% | -17.65% | 9.25% |
| Operating Income | -11.64M | -11.90M | -12.63M | -15.53M | -14.21M | -14.10M | -12.41M | -7.61M | 319.00K | 231.00K | 9.00K | -339.00K | -618.00K | -583.00K | -5.10M | -5.63M | -312.00K | -79.80K | -92.80K | -101.48K | -779.68K | -503.74K | -1.15M | -2.02M | -1.93M | -1.20M | -1.20M | -700.00K | 206.23K |
| Operating Income Ratio | -2,441.09% | -880.25% | -1,244.33% | -10,709.66% | -2,001.83% | -2,256.32% | -2,589.77% | -1,320.83% | 61.70% | 54.10% | 3.36% | -546.77% | -5,150.00% | 0.00% | -272.98% | -444.16% | -48.52% | 0.00% | 0.00% | 0.00% | -20.74% | -12.35% | -29.13% | -52.20% | -48.28% | -28.57% | -31.58% | -20.59% | 6.55% |
| Total Other Income/Expenses | 73.00K | -6.00K | 7.00K | 525.00K | -496.00K | 115.00K | 97.00K | -2.70M | 3.00K | 3.00K | 10.00K | 8.00K | -14.00K | 27.00K | 24.00K | -20.00K | 33.00K | -199.20K | 0.00 | 0.00 | 679.90K | 24.23K | 24.23K | 56.84K | 56.84K | 625.51K | 500.00K | 0.00 | 839.12K |
| Income Before Tax | -11.57M | -11.91M | -12.62M | -15.00M | -14.71M | -13.99M | -12.31M | -10.31M | 322.00K | 234.00K | 19.00K | -331.00K | -632.00K | -556.00K | -5.08M | -5.80M | -279.00K | 0.00 | 0.00 | 0.00 | -722.70K | -479.51K | -1.23M | -1.96M | -1.54M | -1.30M | -700.00K | 0.00 | 139.12K |
| Income Before Tax Ratio | -2,425.79% | -880.70% | -1,243.65% | -10,347.59% | -2,071.69% | -2,237.92% | -2,569.52% | -1,789.93% | 62.28% | 54.80% | 7.09% | -533.87% | -5,266.67% | 0.00% | -271.70% | -457.41% | -43.39% | 0.00% | 0.00% | 0.00% | -19.22% | -11.76% | -31.02% | -50.73% | -38.72% | -30.95% | -18.42% | 0.00% | 4.42% |
| Income Tax Expense | 0.00 | 6.00K | -2.00K | 1.00K | 110.00K | -115.00K | -192.00K | 5.40M | -6.00K | -6.00K | -20.00K | -652.00K | -10.31M | 10.90M | -48.00K | 3.10M | 0.00 | -4.36K | 92.80K | 710.86K | -28.24K | -48.45K | 149.87K | 103.91K | -762.83K | 200.00K | -1.10M | -100.00K | 3.53K |
| Net Income | -11.57M | -11.91M | -12.62M | -15.01M | -14.82M | -13.87M | -12.31M | -10.31M | 322.00K | 234.00K | 19.00K | 305.00K | 9.66M | -11.51M | -5.08M | -5.80M | -287.00K | -75.44K | -92.80K | -812.34K | -722.70K | -479.51K | -1.23M | -2.18M | -1.54M | -1.30M | -600.00K | -600.00K | 135.60K |
| Net Income Ratio | -2,425.79% | -881.14% | -1,243.45% | -10,348.28% | -2,087.18% | -2,219.52% | -2,569.52% | -1,789.93% | 62.28% | 54.80% | 7.09% | 491.94% | 80,516.67% | 0.00% | -271.70% | -457.41% | -44.63% | 0.00% | 0.00% | 0.00% | -19.22% | -11.76% | -31.02% | -56.35% | -38.72% | -30.95% | -15.79% | -17.65% | 4.31% |
| EPS | -8.19 | -10.08 | -11.19 | -22.24 | -39.38 | -48.80 | -43.54 | -166.33 | 27.86 | 20.50 | 1.78 | 28.61 | 906.29 | -1.08K | -528.72 | -742.35 | -34.84 | -8.21 | -10.10 | -98.42 | -92.38 | -61.30 | -156.91 | -275.16 | -237.12 | -210.36 | -97.17 | -117.32 | 0.38 |
| EPS Diluted | -8.19 | -10.08 | -11.19 | -22.24 | -39.38 | -48.80 | -43.54 | -166.33 | 27.86 | 20.50 | 1.78 | 28.61 | 906.29 | -1.08K | -528.72 | -742.35 | -34.84 | -8.21 | -10.10 | -98.42 | -92.38 | -61.30 | -156.15 | -275.16 | -237.12 | -204.63 | -97.17 | -113.64 | 0.38 |
| Weighted Avg Shares Out | 1.41M | 1.18M | 1.13M | 674.58K | 376.29K | 284.28K | 282.67K | 61.99K | 11.56K | 11.41K | 10.66K | 10.66K | 10.66K | 10.66K | 9.60K | 7.81K | 8.24K | 9.19K | 9.19K | 8.25K | 7.82K | 7.82K | 7.82K | 7.92K | 6.51K | 6.18K | 6.18K | 5.11K | 360.60K |
| Weighted Avg Shares Out (Dil) | 1.41M | 1.18M | 1.13M | 674.58K | 376.29K | 284.28K | 282.67K | 61.99K | 11.56K | 11.41K | 10.66K | 10.66K | 10.66K | 10.66K | 9.60K | 7.81K | 8.24K | 9.19K | 9.19K | 8.25K | 7.82K | 7.82K | 7.86K | 7.92K | 6.51K | 6.35K | 6.18K | 5.28K | 360.60K |
BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study
SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announced that the next Data Safety Monitoring Board (DSMB) meeting for the...
BioCardia Reports First Quarter 2023 Business Highlights and Financial Results
SUNNYVALE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the first quarter of 2023 and filed its quarterly...
BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications
SUNNYVALE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted Patent Number 11,642,377: titled,...
BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023
SUNNYVALE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three months ended March...
BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available
SUNNYVALE, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases has made available two presentations from the “Next Generation Cardiovascular Drug Development Summit...
BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies
SUNNYVALE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologies for delivery...
BioCardia, Inc. (BCDA) Q4 2022 Earnings Call Transcript
BioCardia, Inc. (NASDAQ:BCDA ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Peter Altman - President & CEO David McClung - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright Kumaraguru Raja - Roth Capital...
BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results
SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2022 and filed its...
BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023
SUNNYVALE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31,...
Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting
New Data from Roll-in Cohort of Trial Shows Progression of Patients from Baseline through One and Two Years
Source: https://incomestatements.info
Category: Stock Reports